1-[(4-硝基苯基)甲基]吡咯烷 | 133851-67-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[(4-硝基苯基)甲基]吡咯烷
• 中文别名: 吡咯烷,1-[(4-硝基苯基)甲基]-
• 英文名称: 1-(4-nitro-benzyl)-pyrrolidine
• 英文别名: 4-(pyrrolidino-methyl)-nitrobenzene；1-(4-Nitrobenzyl)pyrrolidine；1-[(4-nitrophenyl)methyl]pyrrolidine
• CAS: 133851-67-9
• 化学式: C₁₁H₁₄N₂O₂
• mdl: MFCD02051488
• 分子量: 206.244
• InChiKey: YRULNKOFMFLCNV-UHFFFAOYSA-N

物化性质

• 沸点：
  319.7±17.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  49.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-[(4-Nitrophenyl)methyl]pyrrolidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-[(4-Nitrophenyl)methyl]pyrrolidine
CAS number: 133851-67-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H14N2O2
Molecular weight: 206.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-[(4-硝基苯基)甲基]吡咯烷 在 β-环糊精 、 2-碘酰基苯甲酸 作用下， 以 水 为溶剂， 反应 7.0h， 以80%的产率得到1-[(4-硝基苯基)甲基]吡咯
  参考文献：
  名称：

  o-Iodoxybenzoic acid (IBX): a versatile reagent for the synthesis of N-substituted pyrroles mediated by β-cyclodextrin in water

  摘要：

  o-Iodoxybenzoic acid (IBX), a very mild and efficient hypervalent iodine(V) reagent, aromatizes diversely substituted 1-benzylpyrrolidines and N-substituted L-proline analogues to the corresponding substituted pyrroles in good to excellent yields under mild conditions mediated by beta-cyclodextrin in water at room temperature. To the best of our knowledge, this is the first report on IBX, promoting complete aromatization leading to N-benzylpyrroles from the corresponding saturated five membered heterocyclic derivatives in water medium. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.06.077
• 作为产物：
  描述：

  对硝基溴化苄 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 1-[(4-硝基苯基)甲基]吡咯烷
  参考文献：
  名称：

  [EN] CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
  [FR] PYRIMIDINES INHIBITRICES DE CHK-, PDK- ET DE AKT, PRODUCTION ET UTILISATION DE CES COMPOSES COMME AGENTS PHARMACEUTIQUES

  摘要：

  这项发明涉及通式（I）的嘧啶衍生物作为激酶抑制剂，它们的生产以及它们作为治疗各种疾病的药物的用途。

  公开号：

  WO2004048343A1

文献信息

• [EN] QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE DE QUINOLONE POUR LE TRAITEMENT DES TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005097752A1

  公开（公告）日：2005-10-20

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开和声明了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择地取代的苯基、吡啶基或嘧啶基，取代基R1、R4、R10、R11、R19和R20如规范中定义，包含它们的药物组合物，以及在治疗癌症等高增殖性疾病中使用它们的方法。
• [EN] QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER<br/>[FR] DERIVES DE QUINAZOLINE A UTILISER CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2006040526A1

  公开（公告）日：2006-04-20

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及式(I)喹唑啉衍生物或其药物可接受的盐、溶剂化物或前药，其中p、R1、q、R2、R3、R4、R5、环A、X1、R6、r和R7各自具有说明书中定义的任何含义；其制备方法、含有它们的药物组合物以及它们在制造用于治疗细胞增殖障碍或治疗与血管生成和/或血管通透性相关的疾病状态的药物中的应用。
• Metal‐Free Deoxygenation of Amine <i>N</i> ‐Oxides: Synthetic and Mechanistic Studies
  作者：William Lecroq、Jules Schleinitz、Mallaury Billoue、Anna Perfetto、Annie‐Claude Gaumont、Jacques Lalevée、Ilaria Ciofini、Laurence Grimaud、Sami Lakhdar

  DOI：10.1002/cphc.202100108

  日期：2021.6.16

  unprecedented combination of light and P(III)/P(V) redox cycling for the efficient deoxygenation of aromatic amine N-oxides. Moreover, we discovered that a large variety of aliphatic amine N-oxides can easily be deoxygenated by using only phenylsilane. These practically simple approaches proceed well under metal-free conditions, tolerate many functionalities and are highly chemoselective. Combined experimental

  我们在此报告了一种前所未有的光和 P(III)/P(V) 氧化还原循环的组合，用于芳香胺N-氧化物的有效脱氧。此外，我们发现仅使用苯基硅烷就可以轻松地对多种脂肪胺N-氧化物进行脱氧。这些实际上简单的方法在无金属条件下可以很好地进行，耐受许多功能并且具有高度的化学选择性。结合实验和计算研究，能够深入了解控制芳香族和脂肪族胺N-氧化物反应性的因素。
• 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE
  申请人：Player R. Mark

  公开号：US20080114007A1

  公开（公告）日：2008-05-15

  The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R 101 and R 200 are described in the specification.

  本发明针对当前对选择性和强效蛋白酪氨酸激酶抑制剂的需求，提供对c-fms激酶的强效抑制剂。本发明涉及以下式I的新化合物： 或其盐、对映体、互变异构体、结晶、多晶型、无定形、溶剂化物、水合物、酯、前药或代谢物形式，其中A、Y、Z、R 101 和R 200 在说明书中有描述。
• A practical catalytic reductive amination of carboxylic acids
  作者：Emma L. Stoll、Thomas Tongue、Keith G. Andrews、Damien Valette、David J. Hirst、Ross M. Denton

  DOI：10.1039/d0sc02271c

  日期：——

  reductive alkylation reactions of amines using carboxylic acids as nominal electrophiles. The two-step reaction exploits the dual reactivity of phenylsilane and involves a silane-mediated amidation followed by a Zn(OAc)2-catalyzed amide reduction. The reaction is applicable to a wide range of amines and carboxylic acids and has been demonstrated on a large scale (305 mmol of amine). The rate differential between

  我们报道了使用羧酸作为标称亲电子试剂的胺的还原烷基化反应。该两步反应利用了苯基硅烷的双重反应性，涉及硅烷介导的酰胺化，然后是 Zn(OAc) 2催化的酰胺还原。该反应适用于多种胺和羧酸，并已得到大规模证明（305 mmol 胺）。抗逆转录病毒药物马拉韦罗的聚合合成中体现了叔酰胺中间体和仲酰胺中间体的还原速率差异。机理研究表明，酰胺化步骤中残留的 0.5 当量羧酸负责生成具有增强反应性的硅烷还原剂，从而可以还原以前在锌/苯基硅烷体系中不反应的仲酰胺。